Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Novartis (Syntometrine Drug)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

An obstetric combination drug. The drug is used in the final stage of labor and the components are synthetically produced oxytocin, a human hormone produced in the hypothalamus and ergometrine, an alpha-adrenergic, dopaminergic and serotonin (5-HT2) receptor agonist.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Basel
  • Switzerland

Novartis (Syntometrine Drug) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request full access to PitchBook

Novartis (Syntometrine Drug) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request full access to PitchBook